Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study.

Wang K, Gerke TA, Chen X, Prosperi M.

Cancer Med. 2019 Dec;8(17):7399-7407. doi: 10.1002/cam4.2500. Epub 2019 Oct 8.


BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions.

Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M.

Cancer Med. 2018 Oct;7(10):5272-5280. doi: 10.1002/cam4.1747. Epub 2018 Sep 11.


The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.

Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H.

Eur J Cancer. 2015 Apr;51(6):725-33. doi: 10.1016/j.ejca.2015.02.003. Epub 2015 Feb 23.


Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.

Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV.

BJU Int. 2012 Nov;110(9):1252-6. doi: 10.1111/j.1464-410X.2012.11118.x. Epub 2012 May 4.


Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.


Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA.

Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.


The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.

Anderson-Carter I, Posielski N, Liou JI, Khemees TA, Downs TM, Abel EJ, Jarrard DF, Richards KA.

Urol Oncol. 2019 Feb;37(2):130-137. doi: 10.1016/j.urolonc.2018.11.017. Epub 2018 Dec 7.


Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.


Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):66-76. doi: 10.1038/s41391-018-0087-0. Epub 2018 Sep 13.


Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.

Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF.

Ann Intern Med. 2019 Sep 3;171(5):318-327. doi: 10.7326/M18-2753. Epub 2019 Aug 20.


PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.

Patel AA, Chen MH, Renshaw AA, D'Amico AV.

JAMA. 2007 Oct 3;298(13):1533-8.


Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study.

Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, Mucci LA, Signorello LB.

Prostate. 2015 Sep;75(13):1384-93. doi: 10.1002/pros.23019. Epub 2015 May 27.


Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study.

Liu JC, Hao WR, Hsu YP, Sung LC, Kao PF, Lin CF, Wu AT, Yuan KS, Wu SY.

Oncotarget. 2016 Oct 4;7(40):65270-65283. doi: 10.18632/oncotarget.11263.


Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.

Mikkelsen MK, Thomsen FB, Berg KD, Jarden M, Larsen SB, Hansen RB, Brasso K.

Scand J Urol. 2017 Dec;51(6):464-469. doi: 10.1080/21681805.2017.1362032. Epub 2017 Aug 23.


More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.


A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.


Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Eur Urol. 2014 Jan;65(1):177-85. doi: 10.1016/j.eururo.2012.08.070. Epub 2012 Sep 7.


A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States.

Lipworth L, Fazio S, Kabagambe EK, Munro HM, Nwazue VC, Tarone RE, McLaughlin JK, Blot WJ, Sampson UK.

Clin Epidemiol. 2013 Dec 19;6:15-25. doi: 10.2147/CLEP.S53492. eCollection 2014.


PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.


Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2017 Apr;3(2-3):212-220. doi: 10.1016/j.euf.2016.05.004. Epub 2016 Jun 2.


Supplemental Content

Support Center